Glaucoma, Parkinson's disease and neurodegeneration

被引:0
|
作者
Balci, Sevcan Yildiz [1 ]
Eraslan, Muhsin [2 ]
Temel, Ahmet [2 ]
机构
[1] Igdir Devlet Hastanesi, Oftalmol Klin, Igdir, Turkey
[2] Marmara Univ, Tip Fak Hastanesi, Oftalmol Anabilim Dali, Ust Kaynarca, Pendik, Turkey
来源
MARMARA MEDICAL JOURNAL | 2015年 / 28卷 / 01期
关键词
Irreversible vision loss; Neurodegenerative disorders; Neuroprotective therapy;
D O I
10.5472/MMJ.2015.03691.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glaucoma is a disease that causes irreversible vision loss characterized by progressive retinal ganglion cell (RGC) death. The mechanisms independent of intraocular pressure are also implicated in glaucomatous degeneration pathogenesis and numerous similarities exist between glaucoma and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. Although, there is a common pathway between glaucoma and neurodegenerative disorders, pathogenesis of the relationship between neurodegenerative disorders and glaucoma remains poorly undefined. Optical coherence tomography (OCT), non-invasively quantifies the thickness of the retinal nerve fiber layer (RNFL) which is effected due to RGC damage in glaucomatous patients. Recently, RNFL thickness measurements have been studied by using OCT in several neurodegenerative conditions, including Parkinson's disease. The RNFL is unique as a model of neurodegeneration where the changes in its structure is represented with axonal damage. RNFL thickness measurements are important in neurodegenerative disorders which are characterized with neuronal loss and have common pathogenesis with glaucoma. In this review, we emphasize the relationship between glaucoma, Parkinson's disease and neurodegeneration.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 50 条
  • [31] Cerebrospinal fluid markers of neurodegeneration in Parkinson's disease
    Vranova, H.
    Nevrly, M.
    Mares, J.
    Kanovsky, P.
    Stejskal, D.
    MOVEMENT DISORDERS, 2009, 24 : S285 - S286
  • [32] Technology Insight: imaging neurodegeneration in Parkinson's disease
    David J Brooks
    Nature Clinical Practice Neurology, 2008, 4 : 267 - 277
  • [33] Sleep and Neurodegeneration in a Mouse Model of Parkinson's Disease
    Martin, T. Gallego
    Chuan, B.
    Callio, J.
    Guo, L.
    Obidike, N.
    Shah, F.
    Bueno, M.
    Chu, C. T.
    Mora, A. L.
    O'Donnell, C. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [34] Retinal changes in Parkinson's disease and glaucoma
    Matlach, Juliane
    Wagner, Martin
    Malzahn, Uwe
    Schmidtmann, Irene
    Steigerwald, Frank
    Musacchio, Thomas
    Volkmann, Jens
    Grehn, Franz
    Goebel, Winfried
    Klebe, Stephan
    PARKINSONISM & RELATED DISORDERS, 2018, 56 : 41 - 46
  • [35] Angiogenin and tRNA fragments in Parkinson's disease and neurodegeneration
    Prehn, Jochen H. M.
    Jirstrom, Elisabeth
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (04): : 442 - 446
  • [36] Lewy pathology and neurodegeneration in premotor Parkinson's disease
    Del Tredici, Kelly
    Braak, Heiko
    MOVEMENT DISORDERS, 2012, 27 (05) : 597 - 607
  • [37] Methylation status in Parkinson's disease and neurodegeneration processes
    Obeid, R.
    Dillmann, U.
    Schadt, A.
    Fassbender, K.
    Herrmann, W.
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (02) : 244 - 244
  • [38] ER stress and Parkinson's disease: relevance to neurodegeneration
    Hasegawa, Takafumi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 40P - 40P
  • [39] Speech difficulties and dopaminergic neurodegeneration in Parkinson's Disease
    Polychronis, S.
    Ribba, B.
    Nasios, G.
    Dardiotis, E.
    Pagano, G.
    MOVEMENT DISORDERS, 2023, 38 : S566 - S566
  • [40] Natural Products Combating Neurodegeneration: Parkinson's Disease
    Solayman, Md.
    Islam, Md. Asiful
    Alam, Fahmida
    Khalil, Md. Ibrahim
    Kamal, Mohammad Amjad
    Gan, Siew Hua
    CURRENT DRUG METABOLISM, 2017, 18 (01) : 50 - 61